In a surprise move, the FDA has named the longtime leader of its oncology department, Richard Pazdur, M.D., as the new ...
A week into his tenure as head of the FDA’s Center for Drug Evaluation and Research, experts agree that Rick Pazdur is the “ideal fit” to stabilize the agency. And, according to one ex-FDA official, ...
The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on Sunday. Deputy Director Mike Davis is in the running, along with Mary ...
The Food and Drug Administration on Tuesday announced 26-year-old FDA veteran Richard Pazdur will replace a top regulator who ...
Clinical Trials Arena on MSN
FDA’s revolving door reveals Pazdur as new CDER head
"FDA’s revolving door reveals Pazdur as new CDER head" was originally created and published by Clinical Trials Arena, a ...
The FDA on Nov. 11 appointed Richard Pazdur, MD, as the new director of the Center for Drug Evaluation and Research.Pazdur ...
The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of ...
Pazdur, who currently leads the FDA's Oncology Center of Excellence (OCE) and has been with the agency for more than 25 years ...
The U.S. Food and Drug Administration said on Tuesday it appointed the agency's veteran oncology chief Richard Pazdur to ...
Both The U.S. Department of Health and Human Services (HHS) and the FDA announced the appointment of Richard Pazdur, M.D., as ...
George Tidmarsh, the FDA's top drug regulator, has been placed on leave after being accused of abusing his regulatory authority, STAT has learned.
BioCytics is pleased to announce they successfully reached a regulatory milestone for de-risking clinical development plans with a productive FDA INTERACT meeting during which they discussed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback